|1.||Huszar, Dennis: 8 articles (04/2015 - 12/2009)|
|2.||Zinda, Michael: 4 articles (05/2014 - 12/2009)|
|3.||McCoon, Patricia: 3 articles (02/2015 - 12/2009)|
|4.||Houghton, Peter J: 2 articles (02/2015 - 11/2014)|
|5.||Smith, Malcolm A: 2 articles (02/2015 - 11/2014)|
|6.||Tang, Weifeng: 2 articles (02/2015 - 01/2013)|
|7.||Kurmasheva, Raushan T: 2 articles (02/2015 - 11/2014)|
|8.||Hoffman, Ronald: 2 articles (02/2015 - 11/2014)|
|9.||Gu, Lei: 2 articles (05/2014 - 10/2013)|
|10.||Talati, Pooja: 2 articles (05/2014 - 10/2013)|
01/01/2014 - "AZD1480 may be effective against lung tumors driven by an activating EGFR mutation."
03/01/2013 - "Our study provides strong evidence of the anti-tumor growth potency of JAK inhibitor AZD1480 in pediatric solid tumors, providing proof-of principle that inhibition of the JAK/STAT3 signal transduction could be a promising therapeutic target for high-risk pediatric solid tumors."
03/01/2013 - "In vivo studies showed AZD1480 significantly decreased tumor growth and prolonged overall survival in tumor-bearing mice. "
01/01/2013 - "The primary objective of this phase I study was to investigate the safety and tolerability of AZD1480 when administered as monotherapy to patients with solid tumors. "
01/01/2013 - "AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors."
12/01/2011 - "In this study, the in vitro efficacy of AZD1480 was tested in human and murine glioma cell lines. "
12/01/2011 - "AZD1480 treatment effectively blocks constitutive and stimulus-induced JAK1, JAK2, and STAT-3 phosphorylation in both human and murine glioma cells, and leads to a decrease in cell proliferation and induction of apoptosis. "
12/01/2011 - "Furthermore, AZD1480 suppresses STAT-3 activation in the glioma-initiating cell population in GBM tumors. "
|3.||Prostatic Neoplasms (Prostate Cancer)
10/15/2013 - "Efficacy of AZD1480 in disrupting Jak2-Stat5a/b signaling and decreasing prostate cancer cell viability was evaluated in prostate cancer cells. "
10/15/2013 - "Finally, nine of 12 clinical prostate cancers responded to AZD1480 by extensive apoptotic epithelial cell loss, concurrent with reduced levels of nuclear Stat5a/b. "
10/15/2013 - "AZD1480 reduced prostate cancer cell viability sustained by Jak2-Stat5a/b signaling through induction of apoptosis, which was rescued by constitutively active Stat5a/b. "
10/15/2013 - "Patient-derived clinical prostate cancers, grown ex vivo in organ explant cultures, were tested for responsiveness to AZD1480. "
10/15/2013 - "Here, we show that pharmacologic targeting of Jak2-dependent Stat5a/b signaling by the Jak2 inhibitor AZD1480 blocks castrate-resistant growth of prostate cancer. "
|4.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
|5.||Thyroid Neoplasms (Thyroid Cancer)
01/01/2012 - "Here, we tested the efficacy of a JAK1/2- inhibitor, AZD1480, in the in vitro and in vivo growth of thyroid cancer cell lines expressing oncogenic RET. "
01/01/2012 - "AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines."
01/01/2012 - "Thyroid cancer cell lines harboring RET/PTC1 (TPC-1), RET M918T (MZ-CRC1) and RET C634W (TT) alterations, as well as TPC-1 xenografts, were treated with JAK inhibitor, AZD1480. "
01/01/2012 - "In conclusion, AZD1480 effectively blocks proliferation and tumor growth of activated RET- thyroid cancer cell lines, likely through direct RET inhibition in cancer cells as well as by modulation of the microenvironment (e.g. "
|1.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|2.||4- ((4- Fluoro- 2- methyl- 1H- indol- 5- yl)oxy)- 6- methoxy- 7- (3- (pyrrolidin- 1- yl)propoxy)quinazoline (AZD2171)
|3.||salicylhydroxamic acid (SHAM)
|4.||Biological Markers (Surrogate Marker)
|7.||DNA (Deoxyribonucleic Acid)
|10.||Tissue Inhibitor of Metalloproteinase-1
|1.||Heterologous Transplantation (Xenotransplantation)